乳腺癌患者HER2和BRCA1表达与放疗敏感性的关系研究

背景与目的:乳腺癌是全球最常见的女性恶性肿瘤,且发病率仍在不断上升.乳腺癌的术后放疗可有效地改善局部控制率和长期生存率,放疗已成为乳腺癌治疗的主要技术.如何进一步减少患者正常组织的不良反应、提高放疗效果成为研究热点.探讨人表皮生长因子受体2(human epidermal growth factor receptor ...

The relationship between expressions of HER2 and BRCA1 and radiotherapy sensitivity in breast cancer patients

Background and purpose: Breast cancer is the most common malignancy in women worldwide, and its incidence continues to rise. Postoperative radiotherapy for breast cancer can effectively improve local control rate and long-term survival rate. Radiotherapy has become the main technique for breast cancer treatment. How to further reduce the adverse reactions of patients’ normal tissues and improve the curative effect of radiotherapy has become the research focus. This study aimed to investigate the expressions of human epidermal growth factor receptor 2 (HER2) and breast cancer susceptibility gene 1 (BRCA1) in breast cancer patients, and to study the correlation between their expressions and radiation sensitivity, so as to provide the experimental foundation for clinical treatment research. Methods: Breast cancer tissues and adjacent normal breast tissues of 156 breast cancer patients treated in Affiliated Cancer Hospital of Zhengzhou University were collected in this retrospective cohort study, and the tissues of 145 patients with benign breast disease were selected as the control. Real-time fluorescence quantitative polymerase chain reaction (RTFQ-PCR) was used to detect the expressions of HER2 and BRCA1 in tissues. Immunohistochemistry was used to test the HER2and BRCA1 protein expressions in tissues. Relationships of HER2 and BRCA1 expressions with radiation sensitivity and prognosis of breast cancer patients were assessed by Spearman correlation analysis and Kaplan-Meier survival analysis. Results: Compared with the adjacent normal breast tissues and benign breast lesion tissues, breast cancer tissues had high expressions of HER2 mRNA and protein and low expressions of BRCA1 mRNA and protein (P<0.01). After radiotherapy, the local failure rate of HER2 positive patients was significantly higher compared with the HER2 negative patients (P<0.05), while that of BRCA1 positive patients was significantly lower compared with the negative group (P<0.01). The survival time of HER2 positive patients was significantly shorter compared with the HER2 negative patients, while that of BRCA1 positive patients was significantly longer compared with the BRCA1 negative patients (P<0.01). Conclusion: The breast cancer patients with high HER2 gene expression and low BRCA1 gene expression are less sensitive to radiotherapy, providing a new theoretical basis for the clinical treatment of breast cancer patients.